A
Anat Loewenstein
Researcher at Tel Aviv Sourasky Medical Center
Publications - 443
Citations - 12603
Anat Loewenstein is an academic researcher from Tel Aviv Sourasky Medical Center. The author has contributed to research in topics: Macular degeneration & Visual acuity. The author has an hindex of 50, co-authored 406 publications receiving 9997 citations. Previous affiliations of Anat Loewenstein include Johns Hopkins University & Westmead Hospital.
Papers
More filters
Journal ArticleDOI
Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study
Albert J. Augustin,Baruch D. Kuppermann,Paolo Lanzetta,Anat Loewenstein,Xiao-yan Li,Harry Cui,Yehia Hashad,Scott M. Whitcup +7 more
TL;DR: DEX 0.7 significantly improved visual and anatomic outcomes in patients with DME previously treated with laser, intravitreal anti-vascular endothelial growth factor, intrabitreal triamcinolone acetonide, or a combination of these therapies.
Journal ArticleDOI
Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion
TL;DR: The results indicate that Ozurdex has favorable long-term safety profile, and may have a beneficial effect on the visual prognosis in BRVO even in the absence of continuous treatment.
Journal ArticleDOI
Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the ‘DR-Pro-DEX Study’
Matias Iglicki,Dinah Zur,Dinah Zur,Catharina Busch,Mali Okada,Anat Loewenstein,Anat Loewenstein +6 more
TL;DR: This study provides the first long-term evidence that DEX implant has the potential to not only delay progression of DR and PDR development, but may also improve DR severity over 24 months.
Journal ArticleDOI
Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor.
Daphna Mezad-Koursh,Michaella Goldstein,Gad Heilwail,Shiri Zayit-Soudry,Anat Loewenstein,Adiel Barak +5 more
TL;DR: Acute endophthalmitis following anti-VEGF injection appears within days and can result in severe loss of vision if not treated promptly and in the authors' series the clinical and prognostic characteristics were considerably different between culture positive endophTHB cases and culture negative cases.
Journal ArticleDOI
Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
TL;DR: There is growing evidence that this drug may be an effective and safe alternative to the more expensive ranibizumab, although prospective multicentre trials are required to fully investigate this issue.